﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Academy of Medical Sciences of I.R. Iran</PublisherName>
      <JournalTitle>Archives of Iranian Medicine</JournalTitle>
      <Issn>1029-2977</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2012</Year>
        <Month>01</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Five-Year Follow-up Of The Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells in Patients with Myocardial Infarction</ArticleTitle>
    <FirstPage>0</FirstPage>
    <LastPage>0</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Hossein</FirstName>
        <LastName>Ahmadi</LastName>
      </Author>
      <Author>
        <FirstName>Maryam</FirstName>
        <LastName>Moshkani Farahani</LastName>
      </Author>
      <Author>
        <FirstName>Azam</FirstName>
        <LastName>Kouhkan</LastName>
      </Author>
      <Author>
        <FirstName>Kasra</FirstName>
        <LastName>Moazzami</LastName>
      </Author>
      <Author>
        <FirstName>Roghayeh</FirstName>
        <LastName>Fazeli</LastName>
      </Author>
      <Author>
        <FirstName>Hakimeh</FirstName>
        <LastName>Sadeghian</LastName>
      </Author>
      <Author>
        <FirstName>Mehrnaz</FirstName>
        <LastName>Namiri</LastName>
      </Author>
      <Author>
        <FirstName>Manouchehr</FirstName>
        <LastName>Madani-Civi</LastName>
      </Author>
      <Author>
        <FirstName>Hossein</FirstName>
        <LastName>Baharvand</LastName>
      </Author>
      <Author>
        <FirstName>Nasser</FirstName>
        <LastName>Aghdami</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
    </History>
    <Abstract>BACKGROUND:The implantation of a CD133+ bone marrow cell population into an ischemic myocardium has emerged as a promising therapeutic modality for myocardial regeneration and restoration of ventricular contractility. While previous studies have documented the short-term safety and efficacy of CD133+ cell transplantation in patients with acute myocardial infarction, there are few reports of long-term follow-up results. Here, we present the results of long-term follow-up of our acute myocardial infarction patients who were treated with intramyocardial injection of CD133+ cells after coronary bypass graft.  METHODS: After five years, 13 patients in the cell transplantation group and 5 patients in the control group underwent safety and efficacy investigations by New York Heart Association classification and two-dimensional echocardiography (2D echo).  RESULTS:During the five-year study period, no major cardiac adverse events were reported among patients who received CD133+ stem cells. Regarding efficiency, we observed no statistically significant treatment effects for the echocardiographic parameters [left ventricular end-diastolic and end-systolic volumes, and resting ejection fraction] measured during the follow-up period. However, detailed analysis of regional wall motion revealed an improvement in the Wall Motion Score Index from baseline to the six month follow-up, which was maintained during the follow-up period. CONCLUSION:Taken together, the long-term results of the present study indicate that transplantation of CD133+ is a safe and feasible procedure; however, we could not show any major benefits in our patients. Thus, this issue needs to be addressed by conducting other studies with more patients.</Abstract>
  </Article>
</ArticleSet>